A Phase1b Clinical Study of the Oral PI3Kd Inhibitor, Linperlisib, in Patients with B-Cell Lymphomas

被引：1
|
作者：
Qiu, Lugui [1 ,2 ]
Li, Zhiming [3 ]
Huang, Yunhong [4 ]
Liu, Ligen [5 ]
Liu, Lihong [6 ]
Guo, Ye [7 ]
Deng, Lan [8 ]
Yang, Haiyan [9 ]
CA, Zhen, I [10 ,12 ]
Ye, Xu [11 ]
Wang, Zhen
Bao, Hanying [13 ]
Xu, Zusheng [13 ]
Zheng, Binghua [13 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin, Peoples R China
[3] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China
[4] Guizhou Med Univ, Dept Lymphoma, Affiliated Canc Hosp, Guiyang, Peoples R China
[5] Shanghai Jiao Tong Univ, Tongren Hosp, Dept Hematol, Sch Med, Shanghai, Peoples R China
[6] Hebei Med Univ, Dept Hematol, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[7] Tongji Univ, Shanghai Dongfang Hosp, Dept Med Oncol, Shanghai, Peoples R China
[8] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Hematol, Sch Med, Shanghai, Peoples R China
[9] Univ Chinese Acad Sci, Canc Hosp, Dept Lymphoma, Hangzhou, Peoples R China
[10] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China
[11] Guangzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Guangzhou, Peoples R China
[12] Linyi Canc Hosp, Linyi, Peoples R China
[13] Shanghai Yingli Pharmaceut Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-148276
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3576
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study
    Hao Zhang
    Jiyue Gao
    Zuowei Zhao
    Man Li
    Caigang Liu
    BMC Cancer, 14
  • [42] AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas
    Torka, Pallawi
    Russell, Tara
    Mavis, Cory
    Gu, Juan
    Ghione, Paola
    Barth, Matthew
    Hernandez-Ilizaliturri, Francisco J. J.
    LEUKEMIA & LYMPHOMA, 2023, 64 (06) : 1175 - 1185
  • [43] Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome
    Kracker, Sven
    Curtis, James
    Ibrahim, Mohammad A. A.
    Sediva, Anna
    Salisbury, Jon
    Campr, Vit
    Debre, Marianne
    Edgar, J. David M.
    Imai, Kohsuke
    Picard, Capucine
    Casanova, Jean-Laurent
    Fischer, Alain
    Nejentsev, Sergey
    Durandy, Anne
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (01) : 233 - 236
  • [44] Idelalisib—targeting PI3Kδ in patients with B-cell malignancies
    Jan A. Burger
    Klaus Okkenhaug
    Nature Reviews Clinical Oncology, 2014, 11 : 184 - 186
  • [45] Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies
    M Roschewski
    M Farooqui
    G Aue
    F Wilhelm
    A Wiestner
    Leukemia, 2013, 27 : 1920 - 1923
  • [46] BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
    Moreno, Victor
    Vieito, Maria
    Sepulveda, Juan Manuel
    Galvao, Vladimir
    Hernandez-Guerrero, Tatiana
    Doger, Bernard
    Saavedra, Omar
    Carlo-Stella, Carmelo
    Michot, Jean-Marie
    Italiano, Antoine
    Magagnoli, Massimo
    Carpio, Cecilia
    Pinto, Antonio
    Sarmiento, Rafael
    Amoroso, Barbara
    Aronchik, Ida
    Filvaroff, Ellen
    Hanna, Bishoy
    Wei, Xin
    Nikolova, Zariana
    Brana, Irene
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [47] Phase I Study of On 01910.Na (rigosertib), a Multikinase PI3K Inhibitor in Relapsed/Refractory B-Cell Malignancies
    Roschewski, Mark
    Farooqui, Mohammed
    Aue, Georg
    Mo, Clifton C.
    Valdez, Janet
    Soto, Susan
    Perez-Galan, Patricia
    Wilhelm, Francois
    Wiestner, Adrian
    BLOOD, 2012, 120 (21)
  • [48] Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies
    Roschewski, M.
    Farooqui, M.
    Aue, G.
    Wilhelm, F.
    Wiestner, A.
    LEUKEMIA, 2013, 27 (09) : 1920 - 1923
  • [49] BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
    Victor Moreno
    Maria Vieito
    Juan Manuel Sepulveda
    Vladimir Galvao
    Tatiana Hernández-Guerrero
    Bernard Doger
    Omar Saavedra
    Carmelo Carlo-Stella
    Jean-Marie Michot
    Antoine Italiano
    Massimo Magagnoli
    Cecilia Carpio
    Antonio Pinto
    Rafael Sarmiento
    Barbara Amoroso
    Ida Aronchik
    Ellen Filvaroff
    Bishoy Hanna
    Xin Wei
    Zariana Nikolova
    Irene Braña
    Nature Communications, 14
  • [50] Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
    Dickinson, Michael
    Briones, Javier
    Herrera, Alex F.
    Gonzalez-Barca, Eva
    Ghosh, Nilanjan
    Cordoba, Raul
    Rutherford, Sarah C.
    Bournazou, Eirini
    Labriola-Tompkins, Emily
    Franjkovic, Izolda
    Chesne, Evelyne
    Brouwer-Visser, Jurriaan
    Lechner, Katharina
    Brennan, Barbara
    Nueesch, Eveline
    DeMario, Mark
    Ruettinger, Dominik
    Kornacker, Martin
    Hutchings, Martin
    BLOOD ADVANCES, 2021, 5 (22) : 4762 - 4770
12345